US 9,173,853 B2Granted

Composition for gene delivery

AssigneeChong Kun Dang Pharmaceutical Corp.

InventorsYoung Nam Lee, Ho Young Hwang, Sang Myoung Noh, Hee-Jeong Cho, Ah-Reum Chae, Ji Hee Lee, Min Hyo Ki, Jong Lae Lim

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

Disclosed is a pharmaceutical composition for gene delivery, comprising: (i) a gene; (ii) a water-soluble chitosan; (iii) a thiamine pyrophosphate or a pharmaceutically acceptable salt thereof; (iv) a protamine or a pharmaceutically acceptable salt thereof; and (v) a neutral or anionic phospholipid. The composition can introduce a gene into cells safely and effectively. Composed of non-toxic and injectable components, the composition is safe for the body and can be advantageously commercialized. Notably, it can deliver a gene at high efficiency in vivo as well as in vitro, and is stable in the blood.

Claims8

Dependent claims

A pharmaceutical composition for gene delivery, comprising:

(i) a gene;
(ii) a water-soluble chitosan;
(iii) a thiamine pyrophosphate or a pharmaceutically acceptable salt thereof;
(iv) a protamine or a pharmaceutically acceptable salt thereof;
and
(v) a neutral or anionic phospholipid wherein the composition contains nanoparticle complexes ranging in diameter from 10 to 500 nm, and wherein the composition contains the chitosan in an amount of from 10 to 3,000 weight parts, the thiamine pyrophosphate or a pharmaceutically acceptable salt thereof in an amount of from 1 to 1,000 weight parts, the protamine or a pharmaceutically acceptable salt thereof in an amount of from 10 to 1,000 weight parts, and the neutral or anionic phospholipid in an amount of from 100 to 5,000 weight parts, based on 100 weight parts of the gene.

3 more elements

Dependencies are inferred from the claim text.

Facts

Application: 14/357,375Filed 9 Nov 2012
Priority: KR 10-2011-011708210 Nov 2011
Published: US 2015/0110876 A123 Apr 2015
Granted: 3 Nov 2015
Term ends: Not estimatedThe source records don’t support an estimate.

Classification22 codes

A61K 9/5161
Organic macromolecular compounds; Dendrimers: polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/127
Dispersions; Emulsions: synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 9/19
Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles: lyophilised , i.e.…